Inventor · disambiguated record
Margaret Lindorfer
Also filed as: LINDORFER MARGARET · LINDORFER MARGARET A
10 granted patents·5 pending applications·33 citations·filing 2002–2022
86Inventor score
Top patents by PatentIndex Score
15 records- 0195US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 0294US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 0394US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 0480US10035848B2Antibody targeting cell surface deposited complement protein C3d and use thereofUS HEALTH·Filed 2015·Granted Jul 31, 2018·4 cites·25 claims
- 0580US7858087B2Enhancing the efficacy of immunotherapies by supplementing with complementUNIV VIRGINIA·Filed 2007·Granted Dec 28, 2010·2 cites·7 claims
- 0680US2024117064A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 0777US12448459B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Oct 21, 2025·0 cites·23 claims
- 0872US12275797B2Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereofGENMAB HOLDING B V·Filed 2019·Granted Apr 15, 2025·1 cites·18 claims
- 0964US2020270359A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING BV·Filed 2018·Application pending·0 cites
- 1059US7255858B2Enhancing the efficacy of immunotherapies by supplementing with complementUNIV VIRGINIA·Filed 2002·Granted Aug 14, 2007·1 cites·2 claims
- 1159US2023399414A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 1255US11384139B2Antibody targeting cell surface deposited complement protein C3d and use thereofUS HEALTH·Filed 2018·Granted Jul 12, 2022·0 cites·20 claims
- 1349US7378094B2Therapeutic uses of complement receptor 2UNIV VIRGINIA·Filed 2002·Granted May 27, 2008·0 cites·15 claims
- 1446US2024252635A1Pharmaceutical compositions comprising bispecific anti-cd37 antibodiesGENMAB HOLDING B V·Filed 2019·Application pending·0 cites
- 1540US2009004183A1Compositions and Methods for Regulating the Alternative Pathway of ComplementTAYLOR RONALD P·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →